Titre : Double couche lipidique

Double couche lipidique : Questions médicales fréquentes

Termes MeSH sélectionnés :

Hepatitis B virus
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Double couche lipidique : Questions médicales les plus fréquentes", "headline": "Double couche lipidique : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Double couche lipidique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-21", "dateModified": "2025-05-16", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Double couche lipidique" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Membrane artificielle", "url": "https://questionsmedicales.fr/mesh/D008567", "about": { "@type": "MedicalCondition", "name": "Membrane artificielle", "code": { "@type": "MedicalCode", "code": "D008567", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "J01.637.087.500" } } }, "about": { "@type": "MedicalCondition", "name": "Double couche lipidique", "alternateName": "Lipid Bilayers", "code": { "@type": "MedicalCode", "code": "D008051", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "John F Nagle", "url": "https://questionsmedicales.fr/author/John%20F%20Nagle", "affiliation": { "@type": "Organization", "name": "Department of Physics , Carnegie Mellon University , Pittsburgh , Pennsylvania 15213 , United States." } }, { "@type": "Person", "name": "Jinyoung Seo", "url": "https://questionsmedicales.fr/author/Jinyoung%20Seo", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, South Korea." } }, { "@type": "Person", "name": "Sungi Kim", "url": "https://questionsmedicales.fr/author/Sungi%20Kim", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, South Korea." } }, { "@type": "Person", "name": "Ha H Park", "url": "https://questionsmedicales.fr/author/Ha%20H%20Park", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, South Korea." } }, { "@type": "Person", "name": "Jwa-Min Nam", "url": "https://questionsmedicales.fr/author/Jwa-Min%20Nam", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, South Korea." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Plerixafor and resatorvid inhibit hepatitis B virus", "datePublished": "2023-02-20", "url": "https://questionsmedicales.fr/article/36891156", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fcimb.2023.1118801" } }, { "@type": "ScholarlyArticle", "name": "Hepatitis B Virus Research in South Africa.", "datePublished": "2022-08-31", "url": "https://questionsmedicales.fr/article/36146747", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/v14091939" } }, { "@type": "ScholarlyArticle", "name": "Occult Hepatitis B Virus Infection: An Update.", "datePublished": "2022-07-08", "url": "https://questionsmedicales.fr/article/35891484", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/v14071504" } }, { "@type": "ScholarlyArticle", "name": "Mutations in the S gene of hepatitis B virus in three generations of patients with chronic hepatitis B.", "datePublished": "2023-06-12", "url": "https://questionsmedicales.fr/article/37308753", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11262-023-02012-z" } }, { "@type": "ScholarlyArticle", "name": "Chronic Hepatitis B Virus: What an Internist Needs to Know: Serologic Diagnosis, Treatment Options, and Hepatitis B Virus Reactivation.", "datePublished": "2023-02-20", "url": "https://questionsmedicales.fr/article/37001946", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.mcna.2022.12.002" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Technologie, industrie et agriculture", "item": "https://questionsmedicales.fr/mesh/D013676" }, { "@type": "ListItem", "position": 3, "name": "Produits manufacturés", "item": "https://questionsmedicales.fr/mesh/D008420" }, { "@type": "ListItem", "position": 4, "name": "Matériaux biomimétiques", "item": "https://questionsmedicales.fr/mesh/D040761" }, { "@type": "ListItem", "position": 5, "name": "Membrane artificielle", "item": "https://questionsmedicales.fr/mesh/D008567" }, { "@type": "ListItem", "position": 6, "name": "Double couche lipidique", "item": "https://questionsmedicales.fr/mesh/D008051" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Double couche lipidique - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Double couche lipidique", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-16", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Double couche lipidique", "description": "Comment identifier une double couche lipidique ?\nQuels tests peuvent évaluer la fluidité des membranes ?\nQuels indicateurs montrent une défaillance de la membrane ?\nComment les lipides sont-ils analysés dans les membranes ?\nQuels marqueurs biochimiques signalent des anomalies ?", "url": "https://questionsmedicales.fr/mesh/D008051?mesh_terms=Hepatitis+B+virus&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Double couche lipidique", "description": "Quels symptômes indiquent une dysfonction membranaire ?\nComment la fluidité affecte-t-elle la fonction cellulaire ?\nQuels effets sur la santé sont liés aux membranes ?\nQuels signes cliniques sont associés aux membranes ?\nComment les membranes influencent-elles l'immunité ?", "url": "https://questionsmedicales.fr/mesh/D008051?mesh_terms=Hepatitis+B+virus&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Double couche lipidique", "description": "Comment prévenir les maladies liées aux membranes ?\nQuels modes de vie favorisent la santé membranaire ?\nComment éviter l'oxydation des membranes ?\nQuels facteurs environnementaux affectent les membranes ?\nComment le stress influence-t-il la santé membranaire ?", "url": "https://questionsmedicales.fr/mesh/D008051?mesh_terms=Hepatitis+B+virus&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Double couche lipidique", "description": "Quels traitements ciblent les membranes cellulaires ?\nComment les lipides peuvent-ils être manipulés ?\nQuels suppléments peuvent améliorer la santé membranaire ?\nComment les antioxydants aident-ils les membranes ?\nQuels traitements sont utilisés pour les maladies membranaires ?", "url": "https://questionsmedicales.fr/mesh/D008051?mesh_terms=Hepatitis+B+virus&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Double couche lipidique", "description": "Quelles complications peuvent survenir avec des membranes altérées ?\nComment les membranes affectent-elles le cancer ?\nQuels troubles neurologiques sont liés aux membranes ?\nComment les infections impactent-elles les membranes ?\nQuelles sont les conséquences d'une défaillance membranaire ?", "url": "https://questionsmedicales.fr/mesh/D008051?mesh_terms=Hepatitis+B+virus&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Double couche lipidique", "description": "Quels facteurs génétiques influencent la santé membranaire ?\nComment l'alimentation impacte-t-elle les membranes ?\nQuels comportements augmentent le risque de maladies membranaires ?\nComment l'âge affecte-t-il la santé des membranes ?\nQuels facteurs environnementaux sont des risques pour les membranes ?", "url": "https://questionsmedicales.fr/mesh/D008051?mesh_terms=Hepatitis+B+virus&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier une double couche lipidique ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'observation au microscope électronique révèle la structure en double couche." } }, { "@type": "Question", "name": "Quels tests peuvent évaluer la fluidité des membranes ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de diffusion de marqueurs fluorescents peuvent être utilisés." } }, { "@type": "Question", "name": "Quels indicateurs montrent une défaillance de la membrane ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Une augmentation de la perméabilité et des fuites de protéines sont des indicateurs." } }, { "@type": "Question", "name": "Comment les lipides sont-ils analysés dans les membranes ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'analyse par chromatographie permet d'étudier la composition lipidique." } }, { "@type": "Question", "name": "Quels marqueurs biochimiques signalent des anomalies ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés de lipides oxydés peuvent indiquer des anomalies membranaires." } }, { "@type": "Question", "name": "Quels symptômes indiquent une dysfonction membranaire ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles métaboliques et des inflammations peuvent survenir." } }, { "@type": "Question", "name": "Comment la fluidité affecte-t-elle la fonction cellulaire ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Une fluidité altérée peut perturber le transport des protéines et des ions." } }, { "@type": "Question", "name": "Quels effets sur la santé sont liés aux membranes ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des maladies comme l'athérosclérose sont liées à des anomalies des membranes." } }, { "@type": "Question", "name": "Quels signes cliniques sont associés aux membranes ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme l'œdème et la déshydratation peuvent être observés." } }, { "@type": "Question", "name": "Comment les membranes influencent-elles l'immunité ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les membranes régulent l'activation des cellules immunitaires et la signalisation." } }, { "@type": "Question", "name": "Comment prévenir les maladies liées aux membranes ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée riche en acides gras essentiels aide à maintenir la santé." } }, { "@type": "Question", "name": "Quels modes de vie favorisent la santé membranaire ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "L'exercice régulier et l'hydratation adéquate sont essentiels." } }, { "@type": "Question", "name": "Comment éviter l'oxydation des membranes ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Consommer des aliments riches en antioxydants aide à protéger les membranes." } }, { "@type": "Question", "name": "Quels facteurs environnementaux affectent les membranes ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "La pollution et les toxines peuvent endommager les membranes cellulaires." } }, { "@type": "Question", "name": "Comment le stress influence-t-il la santé membranaire ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Le stress chronique peut altérer la composition lipidique des membranes." } }, { "@type": "Question", "name": "Quels traitements ciblent les membranes cellulaires ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme les statines modifient la composition lipidique." } }, { "@type": "Question", "name": "Comment les lipides peuvent-ils être manipulés ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des techniques de nanomédecine utilisent des liposomes pour délivrer des médicaments." } }, { "@type": "Question", "name": "Quels suppléments peuvent améliorer la santé membranaire ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les acides gras oméga-3 sont bénéfiques pour la fluidité membranaire." } }, { "@type": "Question", "name": "Comment les antioxydants aident-ils les membranes ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Ils protègent les membranes contre l'oxydation et le stress oxydatif." } }, { "@type": "Question", "name": "Quels traitements sont utilisés pour les maladies membranaires ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies géniques peuvent corriger des défauts dans les membranes." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des membranes altérées ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des maladies cardiovasculaires et métaboliques peuvent en résulter." } }, { "@type": "Question", "name": "Comment les membranes affectent-elles le cancer ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Des modifications membranaires peuvent favoriser la progression tumorale." } }, { "@type": "Question", "name": "Quels troubles neurologiques sont liés aux membranes ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des maladies comme la sclérose en plaques sont associées à des anomalies membranaires." } }, { "@type": "Question", "name": "Comment les infections impactent-elles les membranes ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les agents pathogènes peuvent perturber l'intégrité des membranes cellulaires." } }, { "@type": "Question", "name": "Quelles sont les conséquences d'une défaillance membranaire ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Une défaillance peut entraîner des troubles métaboliques graves et des inflammations." } }, { "@type": "Question", "name": "Quels facteurs génétiques influencent la santé membranaire ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des mutations dans les gènes liés aux lipides peuvent affecter la membrane." } }, { "@type": "Question", "name": "Comment l'alimentation impacte-t-elle les membranes ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en graisses saturées peut altérer la fluidité membranaire." } }, { "@type": "Question", "name": "Quels comportements augmentent le risque de maladies membranaires ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Le tabagisme et la sédentarité sont des comportements à risque." } }, { "@type": "Question", "name": "Comment l'âge affecte-t-il la santé des membranes ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Le vieillissement peut entraîner une rigidité accrue des membranes cellulaires." } }, { "@type": "Question", "name": "Quels facteurs environnementaux sont des risques pour les membranes ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "L'exposition à des toxines et à des polluants peut endommager les membranes." } } ] } ] }

Sources (10000 au total)

Plerixafor and resatorvid inhibit hepatitis B virus

An increase in the demand for a functional cure has accelerated research on new methods of therapy for chronic hepatitis B, which is mainly focused on restoring antiviral immunity for controlling vira... In this study, we generated the Epro-LUC-HepG2 cell model for screening compounds that target EFTUD2. Plerixafor and resatorvid were screened from 261 immunity and inflammation-related compounds due t... The dual-luciferase reporter assays showed that the EFTUD2 promoter hEFTUD2pro-0.5 kb had the strongest activity. In Epro-LUC-HepG2 cells, plerixafor and resatorvid significantly upregulated the activ... We established a convenient model for screening compounds that target EFTUD2 and further identified plerixafor and resatorvid as novel HBV inhibitors...

Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy.

Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor approved for the treatment for several mature B-cell malignancies. Reactivation of hepatitis B virus (HBV) is a well-described complication in p... We report the first case of HBV reactivation during ibrutinib treatment in an asymptomatic 82-year-old woman with seronegative occult hepatitis B patient (i.e., negative for HBsAg, anti-HBc and anti-H... Our case illustrated that in populations with a high incidence of HBV exposure, systematic screening for HBV exposure is essential prior to ibrutinib treatment, followed by serial monitoring of serolo...

The Investigation of Hepatitis B Vaccine Immune Responses in Occult Hepatitis B Virus-Infected Patients.

There is no effective treatment for occult hepatitis B virus infection (OBI) patients, and immunotherapy may be one of the most promising options. We aim to investigate the underlying mechanism and th... Outpatient OBI patients were screened and randomly divided into treatment (Group A) and control (Group B) groups. At weeks 0, 4, and 24, patients in Group A received a subcutaneous/intramuscular injec... Of the 228 OBI patients, 28 were excluded, and 200 were enrolled for observation. In the end, 44 patients were included in Group A and 39 in Group B after excluding lost cases. At week 0 (baseline), s... Anti-HBs in Group A patients were positively correlated with B lymphocytes (r=0.3431, 0.3087, and 0.3041, respectively) and positively correlated with CD8... Virological reactivation is a risk for OBI patients. Serum hepatitis B surface antibodies were significantly increased after hepatitis B vaccine treatment, the same as the numbers of peripheral blood ...

Hepatitis B virus X gene impacts on the innate immunity and immune-tolerant phase in chronic hepatitis B virus infection.

The immunologic features involved in the immune-tolerant phase of chronic hepatitis B (CHB) virus (HBV) infection are unclear. The hepatitis B virus X (HBx) protein disrupts IFN-β induction by downreg... Children with CHB in the immune-tolerant phase were recruited and followed longitudinally. HBx gene sequencing of infecting HBV strains was performed, and the effects of HBx mutations on the immune-to... A total of 173 children (median age, 6.92 years) were recruited. Patients carrying HBx R87G, I127V and R87G + I127V double mutations exhibited higher cumulative incidences of immune-tolerant phase bre... HBx suppresses IFN-β induction. R87G and I127V mutation restored IFN-β production by preventing MAVS degradation, contributing to curtailing the HBV immune-tolerant phase in CHB patients....

Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus.

Hepatitis B virus (HBV)-human Immunodeficiency virus (HIV) co-infection promotes an aggressive disease course of HBV infection. In the only available non-Cochrane systematic review on antiviral therap... To evaluate the benefits and harms of tenofovir-based antiviral combination regimens versus placebo, tenofovir alone, or non-tenofovir-based antiviral regimen either alone or in combination with HBV f... We searched the Cochrane Hepato-Biliary Group Controlled Trials Register, Cochrane Central Register of Controlled Trials, MEDLINE Ovid, Embase Ovid, LILACS (Bireme), Science Citation Index Expanded (W... We aimed to include randomised clinical trials comparing tenofovir-based antiviral combination regimens (anti-HIV regimen with lopinavir-ritonavir therapy, or any other antiviral therapy, and two drug... We used standard methodological procedures expected by Cochrane. Primary outcomes included all-cause infant mortality, proportion of infants with serious adverse events, proportion of infants with HBV... Five completed trials were included, of which four trials contributed data to one or more of the outcomes. They included a total of 533 participants randomised to tenofovir-based antiviral combination... We do not know what the effects of tenofovir-based antiviral combination regimens are on all-cause infant mortality, proportion of infants with serious adverse events and proportion of mothers with se...